Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN).
It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Marshall Fordyce |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 1200 Brisbane, California 94005 United States | |
| Phone | 650 770 0077 |
| Website | veratx.com |
Stock Details
| Ticker Symbol | VERA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001831828 |
| CUSIP Number | 92337R101 |
| ISIN Number | US92337R1014 |
| Employer ID | 81-2744449 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, Chief Executive Officer and Director |
| Jason S. Carter | Chief Legal Officer |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer |
| Sean P. Grant M.B.A. | Chief Financial Officer |
| David L. Johnson M.B.A. | Chief Opearating Officer |
| Joseph R. Young M.B.A. | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Allen Ebens B.Sc., Ph.D. | Executive Vice President of Research |
| S. Sandra Park J.D. | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance and Operations |
| Debra Charlesworth | Vice President of Corporate Communications |
| Emma Haywood | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | SCHEDULE 13G | Filing |
| Jun 3, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 3, 2025 | ARS | Filing |
| Apr 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |